Moore Capital Management, LP Savara Inc Transaction History

Moore Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$1.0 - $1.47 $100,000 - $147,000	-100,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.71 - $4.91 $71,000 - $491,000	-100,000 Reduced 50.0%	100,000 $448,000
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $237,000 - $1.17 Million	100,000 Added 100.0%	200,000 $474,000
Q3 2018 Nov 14, 2018	BUY	$10.49 - $12.87 $1.05 Million - $1.29 Million	100,000 New	100,000 $1.12 Million
Q1 2018 May 15, 2018	SELL	$8.99 - $14.95 $427,025 - $710,125	-47,500 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$8.26 - $16.76 $392,350 - $796,100	47,500	47,500 $705,000

141

158M

55.6K

600

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $331M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.